clinical trial · NCT07366086
Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta
Amgen·phase3·recruiting·n = 71
Osteogenesis ImperfectaVitamin DCalcium
brief summary
The primary objective of this trial is to evaluate the safety of romosozumab in participants with osteogenesis imperfecta (OI) that have completed Study 20200105, regardless of whether they received investigational product (romosozumab) until the last protocol-specified dose or ended investigational product early.
started
Mar 18, 2026
primary completion
May 21, 2028
completion
May 21, 2028
last updated
Apr 24, 2026
official title
Multicenter, Safety Follow-up Study to Assess Safety of Prior Treatment With Romosozumab in Children and Adolescents With Osteogenesis Imperfecta
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol